Home / Markets / Industries / Health Care
Friday, November 06, 2009
Ziopharm Stock Soars on Cancer Drug News
FOXBusiness
Ziopharm Oncology (ZIOP) offered encouraging data from its cancer drug Zymafos on Friday, announcing an increase in survival of 50% for patients that also underwent chemotherapy.
When the news was announced, the shares of the company, which have risen by fivefold during the year, rose 24%.
The drug, also known as palifosfamide, is designed to treat soft-tissue tumors and is in the final stages of registration for trial approval in the U.S. and internationally.
The drug is administered to patients as an out-patient treatment, and side affects include nausea, fatigue, and hair loss.
